STIEPEL LABS/ROCHE WILL CO-MARKET TOPICAL ACCUTANE IN THE U.S
STIEPEL LABS/ROCHE WILL CO-MARKET TOPICAL ACCUTANE IN THE U.S under the trade name Isotrex. An NDA for the .05% isotretinoin gel is currently pending at FDA for the treatment of acne vulgaris and milder forms of severe recalcitrant acne based on pre-clinical and clinical work conducted by Stiefel. The two companies are currently working on additional studies requested by FDA and are anticipating approval in "late 1987-early 1988." Roche's agreement with Stiefel fits a pattern of licensing/comarketing arrangements Roche has used to broaden its product base, including agreements with DuPont for Versed and with Glaxo for Zantac. Roche recently announced a comarketing agreement covering Miles' calcium channel blocker Baypress (nitrendipine) ("The Pink Sheet" Aug. 25, T&G-1). Steifel will market Isotrex through its 37-person U.S. detail force. Founded in 1847, Stiefel is a closely-held dermatological drug manufacturer based in Coral Gables, Florida. The company's product line includes the top selling Rx wart product, Duofilm, and the Scabene line of pediculucide Rx products. Steifel has wholly owned subsidiaries in 18 foreign countries and Puerto Rico, which generate most of the company's sales.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth